Marcan Pharmaceuticals Inc. Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Marcan Pharmaceuticals Inc. Pharmaceutical Import Records from India — 18 Products, $21.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Marcan Pharmaceuticals Inc. — Pharmaceutical Importer Profile (2026) | 18 Products, $21.9M Trade | TransData Nexus

Marcan Pharmaceuticals Inc.

Pharmaceutical Importer · Canada · Cardiovascular Focus · $21.9M Total Trade · DGFT Verified

Marcan Pharmaceuticals Inc. is a pharmaceutical importer based in Canada with a total trade value of $21.9M across 18 products in 9 therapeutic categories. Based on 704 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Marcan Pharmaceuticals Inc. sources from 12 verified Indian suppliers, with Emcure Pharmaceuticals Limited accounting for 72.1% of imports.

Marcan Pharmaceuticals Inc. — Import Portfolio & Supplier Network

Marcan Pharmaceuticals Inc. import network — 18 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Marcan Pharmaceuticals Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$38.8M	1,891	72.1%
Ipca Laboratories Limited	$4.0M	184	7.4%
Apex Laboratories Private Limited

What Formulations Does Marcan Pharmaceuticals Inc. Import?

Formulation	Value	Ships
Mar-tranexamic acid TAB 500MG 100t ca	$500.0K	10
Furosemide INJ.40MG/4mlx25 mar ca sn	$500.0K	10
Mar-dapsone TAB 100MG 100s marcan ca	$500.0K	10
Potassium chloride sr tablets 600MG.	$473.8K	114
Mar-rizatriptan benzo TAB 10 MG 2x6t ca	$450.0K	9
Ibuprofen tablets USP 400MG (22025 x	$350.0K	7
Mar -allopurinol 200MG (allopurinol	$317.2K	8
Ibuprofen tablets USP 200MG (caplet)	$315.6K	7
Nra-flecainide TAB 100MG 100t ca,batch	$293.4K	8
Mar-mycophenol acid180mg (12x10t)tabs	$284.2K	9
Ondansetron injection 4MG/2ML (2MG/ML)	$256.2K	12
Mar myco mofe oral SUSP USP 200 MG/ML	$250.0K	5
Ibuprofen tablets USP 400MG	$250.0K	5
Mar-diltia cd hcl cap USP 120MG 100c ca	$237.5K	8
Mar-midodrine hcl tablets 2.5MG 100t ca	$230.0K	10

Marcan Pharmaceuticals Inc. imports 1,957 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 18 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Allopurinol	Lipid & Metabolism	$3.3M	67	0.5%	7
2	Diltiazem	Cardiovascular	$3.3M	124	9.0%	3
3	Ibuprofen	Analgesics & Antipyretics	$2.3M	45	0.4%	11
4	Ranitidine	Gastrointestinal	$2.1M	62	9.3%	2
5	Apixaban	Cardiovascular	$1.9M	69	1.0%	15
6	Dapsone	Antimalarial & Antiparasitic	$1.2M	25	3.5%	4
7	Acetaminophen	Analgesics & Antipyretics	$1.2M	24	0.5%	12
8	Furosemide	Diuretics	$1.2M	24	1.7%	8
9	Ezetimibe	Lipid & Metabolism	$1.1M	54	0.2%	19
10	Celecoxib	Analgesics & Antipyretics	$1.0M	74	0.8%	17
11	Febuxostat	Lipid & Metabolism	$1.0M	20	1.2%	7
12	Acarbose	Advanced Diabetes Medications	$783.7K	17	8.9%	3
13	Pravastatin	Cardiovascular	$635.7K	76	1.2%	14
14	Anastrozole	Advanced Oncology	$271.1K	11	0.2%	15
15	Bortezomib	Advanced Oncology	$250.0K	5	1.1%	13
16	Melphalan	Advanced Oncology	$150.0K	3	1.2%	8
17	Amikacin	Advanced Antibiotics	$100.0K	2	0.5%	11
18	Metoclopramide	Gastrointestinal	$100.0K	2	0.4%	6

Marcan Pharmaceuticals Inc. imports 18 pharmaceutical products across 9 categories into Canada totaling $21.9M.

Marcan Pharmaceuticals Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Marcan Pharmaceuticals Inc. is a Canadian pharmaceutical company headquartered in Ottawa, Ontario. Established in 2012, Marcan specializes in the development, manufacturing, and distribution of affordable, high-quality finished-dose generic medications across various therapeutic categories. The company was acquired by Emcure Pharmaceuticals Ltd. in 2015, enhancing its capabilities and market presence. Co-founded by Atul Aggarwal and Nav Aggarwal, Marcan has been instrumental in introducing cost-effective alternatives to brand-name drugs in the Canadian market for over 25 years.

Marcan's product portfolio encompasses over 170 medications, including both brand and generic pharmaceuticals, catering to a wide array of therapeutic areas. The company markets its products to wholesale distributors and retailers, reaching more than 12,500 pharmacies throughout Canada. In 2023, Marcan expanded its operations by becoming a shareholder in Mantra Pharma, further solidifying its position in the generic drug sector. (newswire.ca)

2Distribution Network

Marcan Pharmaceuticals Inc. operates a robust distribution network across Canada, ensuring the efficient delivery of its pharmaceutical products. While specific warehouse locations are not publicly disclosed, the company's strategic partnerships and collaborations, such as the one with Mantra Pharma, suggest a well-established logistics infrastructure capable of supporting nationwide distribution. (newswire.ca) This network is designed to meet the demands of over 12,500 pharmacies, indicating a comprehensive reach within the Canadian healthcare system.

3Industry Role

Marcan Pharmaceuticals Inc. plays a pivotal role in Canada's pharmaceutical supply chain as a primary wholesaler and distributor of generic medications. By offering affordable alternatives to brand-name drugs, Marcan addresses the growing demand for cost-effective healthcare solutions. The company's extensive product portfolio and strategic partnerships position it as a significant player in the Canadian pharmaceutical market, contributing to the accessibility and affordability of essential medications nationwide.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Marcan Pharmaceuticals Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Marcan Pharmaceuticals Inc. imports a diverse range of finished pharmaceutical formulations from India, encompassing 18 products across nine therapeutic categories. The top five imported products—Allopurinol, Diltiazem, Ibuprofen, Ranitidine, and Apixaban—collectively account for 58.9% of the total import value, indicating a moderate concentration in sourcing. This concentration suggests that while Marcan relies on a select group of products, it maintains a diversified supplier base to mitigate risks associated with single-source dependency. The company's engagement with multiple suppliers, including EMCURE PHARMACEUTICALS LIMITED and IPCA LABORATORIES LIMITED, reflects a strategic approach to ensure a stable and reliable supply chain.

2Supply Chain Resilience

Marcan Pharmaceuticals Inc. demonstrates resilience in its Indian supply chain through strategic partnerships with multiple suppliers, including EMCURE PHARMACEUTICALS LIMITED and IPCA LABORATORIES LIMITED. This diversified sourcing strategy reduces dependency on a single supplier, enhancing supply chain stability. The company's focus on importing finished pharmaceutical formulations, rather than raw APIs or bulk drugs, allows for greater control over product quality and compliance with regulatory standards. While specific details regarding backup suppliers and shipping routes are not publicly disclosed, Marcan's established relationships with reputable Indian manufacturers suggest a robust and adaptable supply chain capable of addressing potential disruptions.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the regulation of pharmaceutical imports is overseen by Health Canada, the federal department responsible for promoting and maintaining the health of Canadians. The importation and sale of drugs are governed by the Food and Drugs Act and its associated Regulations, which establish the legal framework for ensuring the safety, efficacy, and quality of health products in Canada. (canada.ca) These regulations apply to human drugs, medical devices, natural health products, and other health-related products, setting forth requirements for importation, distribution, and sale within the Canadian market.

2Import Licensing & GMP

Importers of pharmaceutical products into Canada must hold an Establishment Licence (EL) issued by Health Canada, authorizing them to import specific categories of drugs. The foreign manufacturing site must be listed on the importer's EL, ensuring that imported products meet Canadian standards. Additionally, imported drugs must have a Drug Identification Number (DIN) assigned by Health Canada, indicating that the product has been authorized for sale in Canada. Good Manufacturing Practice (GMP) compliance is mandatory for foreign manufacturers, with Health Canada recognizing certifications such as EU GMP, WHO GMP, and PIC/S. This ensures that imported pharmaceutical products adhere to stringent quality standards, safeguarding public health. (canada.ca)

Marcan Pharmaceuticals Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Marcan Pharmaceuticals Inc.'s focus on importing finished pharmaceutical formulations in therapeutic categories such as cardiovascular, lipid & metabolism, and analgesics & antipyretics aligns with the prevalent health concerns in Canada. The demand for medications in these categories is driven by the high prevalence of cardiovascular diseases, metabolic disorders, and pain-related conditions among the Canadian population. By concentrating on these areas, Marcan addresses critical healthcare needs, ensuring the availability of essential medications and contributing to improved patient outcomes.

2Sourcing Profile

Marcan Pharmaceuticals Inc. employs a strategic sourcing approach by importing finished pharmaceutical formulations from India, focusing on generic drugs. This strategy allows the company to offer cost-effective alternatives to brand-name medications, enhancing accessibility for Canadian patients. India's established pharmaceutical manufacturing industry, with its adherence to international quality standards, makes it a reliable source for high-quality finished formulations. Marcan's sourcing profile reflects a commitment to quality, affordability, and the efficient delivery of essential medications to the Canadian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Marcan Pharmaceuticals Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Marcan Pharmaceuticals Inc., given the company's diversified sourcing strategy and focus on importing finished pharmaceutical formulations. Indian exporters can explore this opportunity by ensuring compliance with Health Canada's regulatory requirements, including GMP certifications and product approvals. By meeting these standards, Indian suppliers can position themselves as viable partners, contributing to Marcan's mission of providing affordable and high-quality medications to the Canadian market.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Marcan Pharmaceuticals Inc. must ensure that their manufacturing facilities are compliant with Good Manufacturing Practice (GMP) standards recognized by Health Canada, such as EU GMP, WHO GMP, or PIC/S certifications. Products must have a Drug Identification Number (DIN) assigned by Health Canada, indicating that the product has been authorized for sale in Canada. Additionally, labeling must be in both English and French, and products must meet Health Canada's batch testing and stability requirements. (canada.ca)

How to Approach

Frequently Asked Questions — Marcan Pharmaceuticals Inc.

What products does Marcan Pharmaceuticals Inc. import from India?

Marcan Pharmaceuticals Inc. imports 18 pharmaceutical products across 9 categories. Top imports: Allopurinol ($3.3M), Diltiazem ($3.3M), Ibuprofen ($2.3M), Ranitidine ($2.1M), Apixaban ($1.9M).

Who supplies pharmaceuticals to Marcan Pharmaceuticals Inc. from India?

Marcan Pharmaceuticals Inc. sources from 12 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (72.1% of imports, $38.8M).

What is Marcan Pharmaceuticals Inc.'s total pharmaceutical import value?

Marcan Pharmaceuticals Inc.'s total pharmaceutical import value from India is $21.9M, based on 704 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Marcan Pharmaceuticals Inc. focus on?

Marcan Pharmaceuticals Inc. imports across 9 categories. The largest: Cardiovascular (26.7%), Lipid & Metabolism (24.8%), Analgesics & Antipyretics (20.4%).

Get Full Marcan Pharmaceuticals Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.